tbuckley/cabot-search huggingface dataset:
CELIAC DISEASE AND GLUTEN-FREE DIET
Journal: JAMA (1963)

Celiac Disease Celiac disease (CD) is one of the most common inherited disorders, with an estimated prevalence rate of 1:100. Originally thought to be a rare disorder, a multi-center study revealed that 1:133 people in the US have CD (1). This translates into 3 million Americans with the disease, although it is estimated that 90 to 95% remain undiagnosed. Prevalence of CD in Canada is thought to be similar as in the US. A high prevalence of CD is also found in individuals with other disorders such as Type 1 diabetes (T1D), autoimmune thyroid disease and Down syndrome. The prevalence of CD in T1D populations around the world ranges between 2.4% to 16.4% (2).
Comparison of serum CYFRA 21-1 and ROMA in distinguishing ovarian cancer from benign pelvic masses.
Authors: Zhong-Qian Li, Robert J Smalley, Curtis L Glover, Savitha Raju, Katherine Falcone, Maryellen Fegely, Kuanglin He, Rachel R Radwan, Timothy R Kettlety
Journal: Journal of Clinical Oncology (2012)

e15565 Background: CYFRA 21-1 is a known lung cancer biomarker. In subjects with ovarian cancer (OC) versus those with benign gynecological diseases, serum CYFRA 21-1 was reported sensitivities (SN) of 44% and 41% at specificity (SP) of 95% for OC detection using an ELISA assay by Hasholzner U (1994) and Tempfer C (1998), respectively. Nolen B (2010) reported a SN of 84.1% and 85.8% and a SP of 85% and 79.3% with a combination of CYFRA 21-1, CA 125 and HE4 using a multiplex bead-based immunoassay in a training and validation set, respectively. We carried out a cohort study to evaluate the serum CYFRA 21-1 as an ovarian cancer biomarker and compared it with ROMA (Risk of Ovarian Malignancy Algorithm), an FDA-cleared ovarian cancer algorithm. Methods: ARCHITECT CYFRA 21-1 assay was used to measure the levels of serum CYFRA 21-1. Single point serum samples from 170 female subjects with a pelvic mass were randomly selected from an archive cohort of female subjects. Among the 170 subjects, 47 had OC (42 with epithelial OC and 5 with low malignant potential tumor) and 123 with benign gynecological diseases. ROMA values were obtained with HE4 EIA and ARCHITECT CA 125 II. Results: For ARCHITECT CYFRA 21-1, the ROC-AUC, cut-off, SN, SP, PPV and NPV were 86%, 1.8 ng/mL, 70.2% (95% CI: 55.1% to 82.7%), 95.1% (95% CI: 89.7% to 98.2%), 84.6% and 89.3%, repectively. For ROMA algorithm, the ROC-AUC, cut-off, SN, SP, PPV and NPV were 92%, 2.44, 89.4% (95% CI: 76.9% to 96.5%), 84.6% (95% CI: 76.9% to 90.4%), 68.9% and 95.4%, repectively. Chi-square test showed an SN for ROMA was significantly higher than that of ARCHITECT CYFRA 21-1 (p &lt; 0.05), and SP for ARCHITECT CYFRA 21-1 was significantly higher than that of ROMA (p &lt; 0.01). Conclusions: In distinguishing OC from benign gynecological diseases, ROMA algorithm appears to be more sensitive than serum ARCHITECT CYFRA 21-1 (p &lt; 0.05), and serum ARCHITECT CYFRA 21-1 appears to be more specific than (p &lt; 0.01) in this cohort study.
“Poisonous” NHS spending on agency staff is coming under control, claim ministers
Authors: Adrian O’Dowd
Journal: BMJ (2016)

NHS trusts’ over-reliance on “poisonous” levels of spending on agency staff to maintain safe care of patients is starting to come under control, MPs have been told.

Almost £300m (€380m; $430m) has been saved on agency staffing in England in the past six months, the health secretary, Jeremy Hunt, told MPs during an evidence session of the House of Commons Health Committee on 9 May. During the committee’s session for its inquiry into the effect of the government’s comprehensive spending review on health and social care, 1 MPs asked what savings the NHS was able to make as a contribution to the £22bn efficiency savings expected of it by the government by …
<i>Susanna Fourment and Her Daughter</i>
Authors: Carrie A. Butt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OPERA-LG: efficient and exact scaffolding of large, repeat-rich eukaryotic genomes with performance guarantees
Authors: Song Gao, Denis Bertrand, Burton K. H. Chia, Niranjan Nagarajan
Journal: Genome biology (2016)

The assembly of large, repeat-rich eukaryotic genomes represents a significant challenge in genomics. While long-read technologies have made the high-quality assembly of small, microbial genomes increasingly feasible, data generation can be expensive for larger genomes. OPERA-LG is a scalable, exact algorithm for the scaffold assembly of large, repeat-rich genomes, out-performing state-of-the-art programs for scaffold correctness and contiguity. It provides a rigorous framework for scaffolding of repetitive sequences and a systematic approach for combining data from different second-generation and third-generation sequencing technologies. OPERA-LG provides an avenue for systematic augmentation and improvement of thousands of existing draft eukaryotic genome assemblies.
The “Black Box” of Racial Disparities in Asthma
Authors: Megan M. Tschudy, Tina L. Cheng
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Strolling With Recovering Addicts
Authors: Mohamed Soliman, Hamza Jalal
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development of a functional assessment of chronic illness therapy questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors: FACT-EGFRI.
Authors: L. I. Wagner, S. E. Rosenbaum, M. Gandhi, K. Webster, M. S. Aneja, D. Cella, J. Brieva, M. E. Lacouture
Journal: Journal of Clinical Oncology (2010)

9046 Background: Dermatologic toxicities (dT) to epidermal growth factor receptor inhibitors (EGFRI) are common and impact quality of life (QoL), which may lead to dose reduction or discontinuation of anticancer therapy. Currently, there are no patient reported outcomes measures (PRO) that assess QoL related to dT from EGFRI treatment. This study describes the development of a PRO questionnaire for dT to EGFRI. Methods: A three-phase process was utilized for item generation, reduction and scale construction. First, a comprehensive literature review was performed and all questions with potential relevance for patients with dT were selected for further evaluation in the form of 62 EGFRI-dT specific items, including some from dermatologic QoL instruments such as the Skindex. Next, a survey and evaluation of these potential items by 12 dT expert physicians and nurses and 20 patients was completed. Finally, the pilot questionnaire was administered to 24 patients with various stages of dT. Item comprehension, relevance and overall content was assessed in semi- structured interviews. Results: In qualitative interviews, patients and experts evaluated the importance of 62 items from the literature and the Skindex. Comments and response frequencies were summarized. Items identified as “quite relevant” or “very relevant” by the majority of experts were retained. Item review and reduction resulted in a 38-item pilot questionnaire. A majority of patients determined the content of the pilot questionnaire to be relevant, comprehensive and easy to understand. Patient input resulted in the omission of 3 items, modification of 6 items, and the addition of 4 items. Final revisions resulted in the FACT-EGFRI, consisting of 18 items encompassing well-being in 3 QoL domains: physical (7 items), social/emotional (6 items), and functional (5 items). Conclusions: The face and content validity of the FACT-EGFRI has been confirmed by EGFRI-dT patients and professionals. Formal validation and reliability testing is planned in a prospective cohort of EGFRI-induced patients with all dT severity grades. The FACT-EGFRI is available at www.facit.org. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Genentech, ImClone Systems, Onyx Amgen, Bayer, Bristol-Myers Squibb, ImClone Systems, Onyx Hana Biosciences
Abstract 16159: Impact of the SYNTAX Score on Revascularization Outcomes for Patients with Multi-Vessel Disease
Authors: C. Michael Gibson, Meagan Doherty, Cassandra Abueg, Lakshmi Gopalakrishnan, Varun Kumar, Sean O'Brian, Maria Grau-Sepulveda, Fred Edwards, Lloyd Klein, William Weintraub
Journal: Circulation (2012)

Background: Questions remain regarding the impact of the SYNTAX score on the relative benefit of coronary artery bypass grafting (CABG) vs percutaneous coronary intervention (PCI) among patients wi...
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
Authors: M. Maio, A. Covre, S. Coral, G. Amato, P. Taverna, J. Lowder, M. Azab, D. Giannarelli, P.G. Natali, A.M. Di Giacomo
Journal: Annals of Oncology (2015)
Assessment and prediction of tablet properties using transmission and backscattering Raman spectroscopy and transmission NIR spectroscopy
Authors: Elisabeth Peeters, Ana Filipa Tavares da Silva, Maunu Toiviainen, Jeroen Van Renterghem, Jurgen Vercruysse, Mikko Juuti, Joao Almeida Lopes, Thomas De Beer, Chris Vervaet, Jean-Paul Remon
Journal: Asian Journal of Pharmaceutical Sciences (2016)

This study investigated whether Raman and Near Infrared (NIR) spectroscopy could predict tablet properties. Granules were produced on a continuous line by varying granulation parameters. Tableting process parameters were adjusted to obtain uniform tablet weight and thickness. Spectra were collected offline and tablet properties determined with traditional analyzing methods. Partial Least Squares (PLS) regression was used to correlate spectral information to tablet properties, but predictive models couldn't be established. Principal component analysis (PCA) was effectively used to distinguish theophylline concentrations and hydration levels and multiple linear regression (MLR) analysis allowed insight on how granulation parameters affect granule and tablet properties.
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy
Authors: Elizabeth J. Shpall, C. Fred LeMaistre, Kent Holland, Edward Ball, Roy B. Jones, Rein Saral, Cindy Jacobs, Shelly Heimfeld, Ronald Berenson, Richard Champlin
Journal: Blood (1997)
Patently confused
Authors: D. Taylor
Journal: BMJ (1997)

The key goals of the European Union relate to preserving peace and increasing prosperity. Free trade—demanding the unhindered movement of goods and services across member states' boundaries—should, many theorists believe, contribute to these ends. But the transition away from nationally focused systems is proving slow and painful. This is not just for workers in enterprises who in the past were protected by local regulations. Broad public and business interests are also being harmed by inconsistencies between tax and allied regimes at the national level and the overall European drive for the free movement of goods. As a result, both public health and pharmaceutical research programmes are at risk of disruption.

An example of the problems arising from the uneasy balance between national and European Union policies is provided by licit and illicit trade in alcohol and tobacco. The movement across the English channel of large quantities of low taxed beer and cigarettes, ostensibly for personal consumption but …
P0007 : Hepatic T cells derived from normothemic machine perfused grafts contained more regulatory T cells and fewer proinflammatory cytokines producing T cells than those from cold storage grafts
Authors: X. Huang, R. Ravikumar, C. Coussios, P. Srinivasan, N. Heaton, P. Friend, W. Jassem, Y. Ma
Journal: Journal of Hepatology (2015)
Tamoxifen and Sexuality: Let's Listen to the Data Speak
Authors: Jonathan J. Beitler, Joanne E. Mortimer, Diane Knapp
Journal: Journal of Clinical Oncology (1999)

Article Tools Correspondence Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1999.17.11.3689 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10550170 Tamoxifen and Sexuality: Let's Listen to the Data Speak Jonathan J. BeitlerxJonathan J. BeitlerSearch for articles by this author Joanne E. MortimerxJoanne E. MortimerSearch for articles by this author , Diane KnappxDiane KnappSearch for articles by this author Show More Montefiore Medical Center, Bronx, NYWashington University School of Medicine, St Louis, MO https://doi.org/10.1200/JCO.1999.17.11.3689 First Page Full Text PDF Figures and Tables © 1999 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse111999In Reply: We agree with Dr Beitler. Our data “suggest” that tamoxifen is less estrogenic on a vaginal mucosa of younger women than older women. However, we can conclude that women on tamoxifen experienced dyspareunia despite this estrogen effect. The literature supports the role of estrogen in improving symptoms of atrophic vaginitis1,2 but does not address dyspareunia per se.On the other hand, the recently published results on health-related quality of life in NSABP P013 also suggest age-related effects of tamoxifen on the vaginal mucosa. The relative risk of vaginal discharge was 2.31 in women ≥ 60 years old, 1.64 in women 50 to 59 years old, and 1.35 in women 35 to 49 years old. Additionally, women assigned to tamoxifen experienced a significant decrease in sexual interest, sexual arousal, and ability to have orgasm.In response to publication of our study, I have received many inquiries from breast cancer survivors about sexual functioning. Sexuality is an important component of quality of life. Unquestionably, well-designed prospective studies of breast cancer patients are needed.1. Leiblum S, Bachmann G, Kemmann E, et al: Vaginal atrophy in the postmenopausal woman. JAMA 249::2195,1983-2198, Crossref, Medline, Google Scholar2. Semmens JP, Wagner G: Estrogen deprivation and vaginal function in postmenopausal women. JAMA 248::445,1982-448, Crossref, Medline, Google Scholar3. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 17::2659,1999-2669, Link, Google Scholar
Pure Yolk Sac Carcinoma of the Mouse Uterus: Report of 8 Cases
Authors: Harold L. Stewart
 3, Bernard Sass, Margaret K. Deringer, Thelma B. Dunn, Lance A. Liotta, Sanemoto Togo
Journal: JNCI Journal of the National Cancer Institute (1984)

This report covered the pathologic features, behavior, metastases, and results of transplantation of pure yolk sac carcinomas that were primary in the uterine horn of 8 mice; 6 mice were strain C3H and 2 were strain HR, and they varied from 10 to 23 months of age. Three of the mice had never been treated. Of the 5 that had, the treatment was different for each mouse. Therefore, treatment could not be correlated with tumor development. At least 5 mice were nulliparous; in fact they had never been mated, so in these some mechanism involving parthenogenesis must have been operative to account for the tumor. The tumors were identified as being primary in the uterus and occupied and distended the cavity of one uterine horn where they were polypoid or plaquelike. The neoplastic yolk cells replaced the endometrial stroma forming a support for the original endometrial glands. In time the tumor cells destroyed many of the endometrial glands. That the glands present in the primary uterine horn tumors were the original glands of the endometrium and not neoplastic glands was attested by their absence from the secondary neoplastic deposits in 4 mice in which the tumor had spread to areas outside the cavity of the uterus and from the neoplastic tissue of the tumor transplants in the recipient mice.
Clinical and molecular predictors of survival in elderly glioblastoma patients treated with radiotherapy and concomitant temozolomide: a multicenter study of aino (Italian Association of Neuro-Oncology)
Authors: G. Lombardi, A. Pace, F. Pasqualetti, S. Rizzato, M. Faedi, E. Anghileri, E. Nicolotto, E. Bazzoli, L. Bellu, V. Villani, A. Fabi, P. Ferrazza, L. Gurrieri, M. Dall'Agata, M. Eoli, A. Della Puppa, A. Pambuku, F. Berti, R. Rudà, V. Zagonel
Journal: Annals of Oncology (2015)
Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
Authors: B. Xu, L. Shen, D. Ye, A. Jappe, H. Wang, R. Yuan, Y. Wu
Journal: Journal of Clinical Oncology (2010)

e13094 Background: The mammalian target of rapamycin (mTOR), a regulator of cell growth, proliferation, and angiogenesis, is commonly dysregulated in cancer. This phase I, randomized, multicenter, open-label study investigated the pharmacokinetics (PK) and tolerability of the mTOR inhibitor everolimus in Chinese patients with advanced solid tumors. Methods: 24 patients with advanced breast cancer (BC; n=6), gastric cancer (GC; n=6), non-small cell lung cancer (NSCLC; n=6), or renal cell carcinoma (RCC; n=6), who were refractory to or unsuitable for standard therapy, were randomized equally to receive oral everolimus 5 or 10 mg/d. PK 24-hour profiles were measured on day 15; trough level (Cmin) was measured on days 2, 8, 15, 16, and 22. Tolerability was assessed continuously. This interim analysis occurred when all patients received 8 weeks of treatment or discontinued prior to week 8. Results: In both cohorts, the most frequent adverse events (AEs) suspected to be everolimus-related were elevated aspartate transaminase, blood triglycerides, and low-density lipoproteins. Incidence of AEs was moderately higher in the 10 mg cohort. Most AEs were grade 1/2. Six (25%) patients (3 in each cohort) experienced grade 3 AEs (fatigue, anemia, hypokalemia, decreased platelet count, upper respiratory tract infection, elevated blood glucose, and alkaline phosphatase,) suspected to be everolimus- related. Incidence of infections was low and not dose-proportional. No laboratory abnormalities were reported as a serious AE. No AEs led to study discontinuation. There were 3 deaths (2 NSCLC, 1 BC) in the 10 mg cohort; none were suspected to be everolimus-related. The 24-hour PK profile revealed a rapid increase in everolimus concentration post-dose peaking at 2.96 (range 1.00–4.00) and 2.00 (range 0.92–6.00) hours in the 5 mg and 10 mg cohorts, respectively. Cmin of everolimus reached steady state by day 8 or earlier. Cmax, Cmin, and AUC0- t were dose-proportional. Conclusions: Everolimus 10 mg/day was well tolerated in Chinese patients with advanced solid tumors. The observed safety and PK profile of everolimus from this study were consistent with previous experience, particularly the pivotal global phase III mRCC study. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Beijing Novartis Pharma, Novartis Novartis, Pfizer Novartis Novartis, Pfizer Novartis